Ipsen has named steven Hildemann as Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance, effective March 2020.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2020-01-28 08:50:002020-01-28 08:50:00Ipsen: New VP and CMO incoming
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2020-01-27_um_09.23.22.png385431Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-01-27 09:01:082020-01-27 09:01:08iOnctura SA bags €15m in Series A round
Ministers from 72 countries came together at the Berlin Agriculture Ministers’ conference to discuss and adopt a joint communiqué on global trade. In it, the ministers agreed to strengthen rule-based free trade.
HepaRegeniX has raised €11m in a Series B. The biotech company will use the proceeds to bring its compound targeting chronic liver disease to the clinic.
Swiss food giant Nestlé will invest up to €1.68bn to support sustainable packaging solutions and to create a market for plastic-free or recycled alternatives.
Karl Naegler, who has been a partner at the investment company Gimv since 2011, has joined the competition. He is now Managing Partner at leading European venture capital firm Wellington Partners.
mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.
Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2020-01-15_um_08.25.34.png364572Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-01-15 07:20:242020-01-15 07:20:24Astellas and Adaptimmune team up in CAR-T development
MercachemSyncom, Bionetix, and ProQinase ink AML contract
Latest NewsBionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing
Ipsen: New VP and CMO incoming
AppointmentsIpsen has named steven Hildemann as Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance, effective March 2020.
iOnctura SA bags €15m in Series A round
Latest NewsMerck KGaA’s 2017 Swiss cancer spin-out iOnctura SA has raised €15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.
Agriculture ministers commit to global trade rules
Latest NewsMinisters from 72 countries came together at the Berlin Agriculture Ministers’ conference to discuss and adopt a joint communiqué on global trade. In it, the ministers agreed to strengthen rule-based free trade.
HepaRegeniX: €11m for liver disease treatment
Latest NewsHepaRegeniX has raised €11m in a Series B. The biotech company will use the proceeds to bring its compound targeting chronic liver disease to the clinic.
Nestlé heavily invests in sustainable packaging
Latest NewsSwiss food giant Nestlé will invest up to €1.68bn to support sustainable packaging solutions and to create a market for plastic-free or recycled alternatives.
Wellington Partners: Sideways move
AppointmentsKarl Naegler, who has been a partner at the investment company Gimv since 2011, has joined the competition. He is now Managing Partner at leading European venture capital firm Wellington Partners.
BioNTech acquires Neon at cheapest for $67m
Latest NewsmRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.
New stromal target overcomes cancer resistance
Latest NewsBritish researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models.
Astellas and Adaptimmune team up in CAR-T development
Latest NewsAdaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.